Patents by Inventor Grethe Karin Martinussen

Grethe Karin Martinussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabalised Tc compositions
    Patent number: 9694092
    Abstract: The present invention relates to stabilised 99mTc radiopharmaceutical compositions of the ligand tetrofosmin, which include an ascorbic acid or ascorbate radioprotectant, in the absence of an antimicrobial preservative. The invention also provides lyophilised kits suitable for the bulk preparation of multiple unit patient doses of 99mTc-tetrofosmin metal complexes. Also disclosed are unit doses of 99mTc-tetrofosmin, together with processes for preparing such unit doses from the lyophilised bulk vial.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: July 4, 2017
    Assignee: GE Healthcare Limited
    Inventors: Ole Kristian Hjelstuen, Grethe Karin Martinussen, Gry Stensrud
  • STABALISED 99MTC COMPOSITIONS
    Publication number: 20110008252
    Abstract: The present invention relates to stabilised 99mTc radiopharmaceutical compositions of the ligand tetrofosmin, which include an ascorbic acid or ascorbate radioprotectant, in the absence of an antimicrobial preservative. The invention also provides lyophilised kits suitable for the bulk preparation of multiple unit patient doses of 99mTc-tetrofosmin metal complexes. Also disclosed are unit doses of 99mTc-tetrofosmin, together with processes for preparing such unit doses from the lyophilised bulk vial.
    Type: Application
    Filed: October 14, 2005
    Publication date: January 13, 2011
    Applicant: GE HEALTHCARE LIMITED
    Inventors: Ole Kristian Hjelstuen, Grethe Karin Martinussen, Gry Stensrud
  • PYRROLINIDIUM DERIVATIVES AS M3 MUSCARINIC RECEPTORS
    Publication number: 20090311178
    Abstract: Compounds of formula (I) in salt or zwitterionic form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: October 14, 2005
    Publication date: December 17, 2009
    Applicant: GE HEALTHCARE LIMITED
    Inventors: Ole Kristian Hjelstuen, Grethe Karin Martinussen, Gry Stensrud